Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cutia Therapeutics's share price for the quarter that ended in Jun. 2023 was HK$24.5. Cutia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 304.0 Mil. Therefore, Cutia Therapeutics's market cap for the quarter that ended in Jun. 2023 was HK$7,448.6 Mil.
Cutia Therapeutics's quarterly market cap
stayed the same
from Jun. 2022 (HK$0.0 Mil) to Dec. 2022 (HK$0.0 Mil) but then
increased
from Dec. 2022 (HK$0.0 Mil) to Jun. 2023 (HK$7,448.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cutia Therapeutics's Enterprise Value for Today is HK$880.3 Mil.
Cutia Therapeutics Market Cap Historical Data
The historical data trend for Cutia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cutia Therapeutics Market Cap Chart
Cutia Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
Market Cap
-
-
2,246.67
Cutia Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Market Cap
-
-
-
7,448.59
3,356.28
Competitive Comparison of Cutia Therapeutics's Market Cap
For the Biotechnology subindustry, Cutia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Market Cap falls into.
Cutia Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cutia Therapeutics's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cutia Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Cutia Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cutia Therapeutics (HKSE:02487) Business Description
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02487 has been successfully added to your